Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

Stock Information for PLUS THERAPEUTICS Inc.

Loading

Please wait while we load your information from QuoteMedia.